Expansion Plans and Foreign Inspections Showcased at CPhI Paris

CPhI Worldwide, Paris (Oct. 3–5)-CPhI Worldwide, the large exhibition of pharmaceutical ingredient suppliers held in Paris last week, revealed two important themes.

First, US and European producers of active pharmaceutical ingredients (APIs) continue to face increased competition from offshore suppliers, particularly from India and China. In a joint press conference and statement, the Synthetic Organic Chemical Manufacturers Association (SOCMA, Washington, DC, www.socma.org) and the European Fine Chemicals Group (EFCG, Brussels, Belgium, www.efcg.cefic.org) responded to these pressures by demanding more active regulatory inspections of offshore manufacturers. See “EFCG and SOCMA Team to Urge for Increased Inspections of Foreign API Manufacturing Facilities,” in this week's ePT.

Second, a number of manufacturers used CPhI to announce expansions and  investments in manufacturing and technologies. Among them were Aptuit, Carbogen Amcis, NPIL Pharma, Archimica, Degussa, and Dowpharma. See “Aptuit Plans Investment in API Infrastructure,” “Carbogen Amcis Plans Expansions,” “NPIL Pharma Launches Dedicated Unit for API Innovation,” “ Archimica Makes Investments in Pharmaceutical Manufacturing and Technologies,” and “Exhibitor News from CPhI Worldwide.” 

Although final figures from this year's show are not yet available, CMP Information, the organizers of CPhI Worldwide, expected this year's show to surpass last year's show in Madrid. That exhibition attracted more than 21,000 visitors and 1459 exhibitors.